Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885 - Wikidata - wikimedia - TriplyDB

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

http://www.wikidata.org/entity/Q27643208

about

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity BRAF Mutation in Hairy Cell Leukemia Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options The Crystal Structure of BRAF in Complex with an Organoruthenium Inhibitor Reveals a Mechanism for Inhibition of an Active Form of BRAF Kinase Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization Pyrazolopyridine Inhibitors of B-Raf V600E . Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics Modification, biological evaluation and 3D QSAR studies of novel 2-(1,3-diaryl- 4,5-dihydro-1H-pyrazol-5-yl)phenol derivatives as inhibitors of B-Raf kinase NCI-60 whole exome sequencing and pharmacological CellMiner analyses Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Molecular dynamics simulations and modelling of the residue interaction networks in the BRAF kinase complexes with small molecule inhibitors: probing the allosteric effects of ligand-induced kinase dimerization and paradoxical activation.Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways.MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells Identification of BRAF inhibitors through in silico screening An in silico study of the molecular basis of B-RAF activation and conformational stability.Characterization and performance of nucleic acid nanoparticles combined with protamine and gold.A proposal: a comprehensive platform to characterize tumors in Chinese and improve success in cancer drug discovery and development.Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.SB202190-induced cell type-specific vacuole formation and defective autophagy do not depend on p38 MAP kinase inhibition.VDA, a method of choosing a better algorithm with fewer validations A physicochemical descriptor-based scoring scheme for effective and rapid filtering of kinase-like chemical space.Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds.Change or die: targeting adaptive signaling to kinase inhibition in cancer cells.ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system.A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF.Finding undetected protein associations in cell signaling by belief propagation.Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain.Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition.A MEK-independent role for CRAF in mitosis and tumor progression.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.The current state of targeted therapy in melanoma: this time it's personal Raf kinases: function, regulation and role in human cancer.

P2860

Q21004109-5AE8C649-BB25-4A65-83F3-95B63A5F05BA Q24298749-CF3A8DE2-C318-4BC7-9A86-8A5D924FF38B Q24606438-09E585E2-5829-41F7-8D35-234AB7B70EDB Q24652600-15523D9C-62CC-453F-8B0D-B9DA96334338 Q27014016-7807AAB4-01C0-4B5D-940A-36317FDB33AE Q27023596-72DAE501-7127-4F0C-B657-E4CA6433C134 Q27654846-43C331CE-1917-43F6-BB11-835BE7D183DE Q27678182-14F0EEE4-8D05-4519-BF02-A45924AF717D Q27684109-CBB7C42B-CCD1-43B7-B51F-BCE4ED7C9814 Q28265862-10FA546A-D304-4AE6-9BBD-11FDAEB2B071 Q28538778-29C0C47D-BB2A-4F46-AC0D-9F54F06A1F8C Q28540834-F06F264D-BD0D-425E-80C9-52F245B1A11F Q28730438-F14D2BAC-936E-4F50-90FF-59B25B14F7F1 Q28744228-CE0C425F-A899-4C45-A2C6-D478A54E2B52 Q29614757-2D793100-8815-4BCE-98CA-9D4FB385E821 Q29616828-543A2243-E985-4F72-9A0A-9A61E4A22AE0 Q30391310-36C688CB-FAE7-41BB-A438-966BB8045FE2 Q30395364-E57CF011-6DCC-4484-A30C-9A34B23DC2CC Q31012806-CDD7F9F8-D060-49EA-A190-330ED42EB66D Q33368383-4CC77C48-0992-4167-888B-E4857C3582E3 Q33485591-C46F1F55-C16F-45E4-955F-74AC0BFFEA57 Q33499568-CD0D5CD7-7916-4417-9E39-E235C86B913B Q33579695-B97678FF-7515-4909-98E4-B5D4CA12D921 Q33906093-FD59C209-2C9C-4554-A45C-B915B829752D Q33996875-0E60327B-45AF-4AA6-AC69-C390646C4015 Q34064348-B692637B-A971-48E9-8D05-96D250647AEE Q34153687-FF195A2A-428B-4D9C-9DF1-63700E9A08B8 Q34207363-1A1515B5-4AB5-4770-90D8-0294D91D54B2 Q34225871-6A1F6816-207D-44BD-A6ED-AF2FAE9F5EED Q34333456-C2B146EA-04F8-4D9A-B152-DE4DF717C71A Q34402062-5C9D3771-D9C0-45D8-BE09-BE11E144415A Q34490371-56BD8923-03DF-415E-A071-BD4385E6CEF0 Q34662736-D60C738F-3D9C-4E75-8DEB-442F7D1878FD Q34669746-1786B6D0-D6CA-458A-9BC1-BE334BFC28DD Q34761941-7435FB1C-130D-4B51-BEA7-9043BEBFFFBA Q35233178-293B5A57-51AF-45C2-B2C5-B9D9CEB0B016 Q35600821-282D4722-51D6-4561-8D7E-105265BC5CC4 Q35679353-1348F1E9-4874-4A33-9383-CA1B72989E4C Q35878248-6DB7F7E6-DC6A-4AD3-9996-74F33BCFB622 Q36002845-9773AB73-D4A7-4F4C-BE90-21C7DD961773

P2860

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

http://www.wikidata.org/entity/Q27643208

description

2006 nî lūn-bûn

@nan

2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Demonstration of a genetic the ...... the kinase inhibitor SB-590885

@ast

Demonstration of a genetic the ...... the kinase inhibitor SB-590885

@en

Demonstration of a genetic the ...... the kinase inhibitor SB-590885

@nl

type

label

Demonstration of a genetic the ...... the kinase inhibitor SB-590885

@ast

Demonstration of a genetic the ...... the kinase inhibitor SB-590885

@en

Demonstration of a genetic the ...... the kinase inhibitor SB-590885

@nl

prefLabel

Demonstration of a genetic the ...... the kinase inhibitor SB-590885

@ast

Demonstration of a genetic the ...... the kinase inhibitor SB-590885

@en

Demonstration of a genetic the ...... the kinase inhibitor SB-590885

@nl

P1433

Q27643208-8753696B-F1EB-4304-A4E0-F35FB92CEE00

P1476

Q27643208-BEBFD8E7-4B90-4341-924B-885013D25869

P2093

Q27643208-0149C8D8-D4F7-4DEB-9692-1165D909F1AB

Q27643208-06E69DA4-5511-4BA2-B564-48EC2BB6F9BE

Q27643208-0BE1EDCC-6A21-42B0-AB3E-29E119A2F9C1

Q27643208-15349B06-4446-444D-AA25-F81B848F87BF

Q27643208-3DD57108-FBED-449D-A695-206ADDB6F724

Q27643208-3EC443DD-E999-432B-8DDF-44BA4690C744

Q27643208-4D0C5F0B-45AE-439E-BB4B-BF5B113EBBA9

Q27643208-4E7C6AFE-6118-4F61-95BF-0621ACB877C0

Q27643208-5A4CF385-04CD-4B7A-8522-E55F6D0A50C4

Q27643208-5D9B15F5-0FAA-4CBF-8868-2E8DF9C3B7FC

P304

Q27643208-B71C4CB1-215E-436B-BF37-9E2CC27C2483

P31

Q27643208-3E01AB55-9839-49E9-BEEF-F461C18EAC00

P356

Q27643208-F89F406A-AA6B-4E2E-A258-A1579680D6BF

P407

Q27643208-F19F3ABD-FAFF-41D4-8A81-5363443E9533

P433

Q27643208-9B25CCC2-521D-43A4-B192-D5F76840CF3E

P478

Q27643208-65B1E334-1920-43A3-BA0D-449F9CB6C5ED

P50

Q27643208-A7AF3751-924C-44DB-99C5-EE65A0D8951F

Q27643208-A9E262D0-DD10-4081-8F90-D3339E482396

Q27643208-C3F13309-F341-47F9-B467-EE107FBBE113

Q27643208-F4D2FFA3-CBED-4909-8F56-D06E7C9AE1C0

P577

Q27643208-D97DFA18-C34F-4F1C-8D61-01598499233B

P698

Q27643208-6AD0EED9-E717-47CE-A7A2-7E32D4C3B067

P356

0008-5472.CAN-06-2554

P1433

Cancer Research

P1476

Demonstration of a genetic the ...... the kinase inhibitor SB-590885

@en

P2093

Alastair J King

http://www.w3.org/2001/XMLSchema#string

Ami S Lakdawala

http://www.w3.org/2001/XMLSchema#string

Andrew K Takle

http://www.w3.org/2001/XMLSchema#string

Cynthia M Rominger

http://www.w3.org/2001/XMLSchema#string

David Chau

http://www.w3.org/2001/XMLSchema#string

David M Wilson

http://www.w3.org/2001/XMLSchema#string

David W Rusnak

http://www.w3.org/2001/XMLSchema#string

Denis R Patrick

http://www.w3.org/2001/XMLSchema#string

Earl W May

http://www.w3.org/2001/XMLSchema#string

Erin Hugger

http://www.w3.org/2001/XMLSchema#string

P304

11100-11105

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-06-2554

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

Keiran S M Smalley

Florian Karreth

P577

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17145850

http://www.w3.org/2001/XMLSchema#string